 |
| ©Elsevier |
Booth, A.,
Noyes, J., Flemming, K., Gehardus, A., Wahlster, P., Jan van der Wilt, G.,
Mozygemba, K., Refolo, P., Sacchini, D., Tummers, M., Rehfuess, E., 2018.
Structured methodology review identified seven (RETREAT) criteria for selecting
qualitative evidence synthesis approaches. Journal of Clinical Epidemiology.
doi:10.1016/j.jclinepi.2018.03.003
Campbell, F.,
Booth, A., Hackett, S., Sutton, A., n.d. Young people who display harmful
sexual behaviors and their families. A qualitative systematic review of their
experiences of professional interventions. Trauma, Violence, Abuse.
Cooper, C.,
Varley-Campbell, J., Booth, A., Britten, N., Garside, R., 2018. Systematic
review identifies six metrics and one method for assessing literature search
effectiveness but no consensus on appropriate use. Journal of Clinical Epidemiology.
doi:10.1016/j.jclinepi.2018.02.025
Cox, M.,
O’Connor, C., Biggs, K., Hind, D., Bortolami, O., Franklin, M., Collins, B.,
Walters, S., Wailoo, A., Channell, J., Albert, P., Freeman, U., Bourke, S.,
Steiner, M., Miles, J., O’Brien, T., McWilliams, D., Schofield, T., O’Reilly,
J., Hughes, R., 2018. The feasibility of early pulmonary rehabilitation and
activity after COPD exacerbations: external pilot randomised controlled trial,
qualitative case study and exploratory economic evaluation. Health Technology Assessment 22, 1–204. doi:10.3310/hta22110
 |
| © Taylor & Francis |
Lipton, R.B.,
Brennan, A., Palmer, S., Hatswell, A.J., Porter, J.K., Sapra, S., Villa, G.,
Shah, N., Tepper, S., Dodick, D., 2018. Estimating the clinical effectiveness
and value-based price range of erenumab for the prevention of migraine in
patients with prior treatment failures: a US societal perspective. Journal of Medical Economics 1–26. doi:10.1080/13696998.2018.1457533
Machaczek,
K.K., Allmark, P., Goyder, E., Grant, G., Ricketts, T., Pollard, N., Booth, A.,
Harrop, D., De-La Haye, S., Collins, K., Green, G., 2018. A scoping study of
interventions to increase the uptake of physical activity (PA) amongst
individuals with mild-to-moderate depression (MMD). BMC Public Health 18.
doi:10.1186/s12889-018-5270-7
Penn, L.,
Rodrigues, A., Haste, A., Marques, M.M., Budig, K., Sainsbury, K., Bell, R.,
Araújo-Soares, V., White, M., Summerbell, C., Goyder, E., Brennan, A., Adamson,
A.J., Sniehotta, F.F., n.d. NHS Diabetes Prevention Programme in England:
formative evaluation of the programme in early phase implementation. BMJ Open
8, e019467. doi:10.1136/bmjopen-2017-019467
Pollard, D.J.,
Brennan, A., Dixon, S., Waugh, N., Elliott, J., Heller, S., Lee, E., Campbell,
M., Basarir, H., White, D., n.d. The cost-effectiveness of insulin pumps
compared to multiple daily injections, both provided with structured education,
for adults with type 1 diabetes: a health economic analysis of the relative
effectiveness of pumps over structured education (REPOSE) randomised controlled
trial. BMJ Open. doi:10.1136/bmjopen-2017-016766
 |
| © SAGE Journals |
Rafia, R.,
Pandor, A., Davis, S., Stevens, J.W., Harnan, S., Clowes, M., Sorour, Y.,
Cutting, R., 2018. Obinutuzumab with Bendamustine for Treating Follicular
Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a
NICE Single Technology Appraisal. Pharmacoeconomics.
doi:10.1007/s40273-018-0645-2
Ren, S.,
Oakley, J.E., Stevens, J.W., 2018. Incorporating Genuine Prior Information
about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-Analyses.
Medical Decision Making. doi:10.1177/0272989X18759488
Rowen, D.L.,
Mulhern, B., Stevens, K., Vermaire, E., n.d. Estimating a Dutch value set for
the paediatric preference-based CHU-9D using a discrete choice experiment with
duration. Value in Health.
Shah, K., Tsuchiya,
A., Wailoo, A., n.d. Valuing health at the end of life: A review of stated
preference studies in the social sciences literature. Social Science Medicine.
doi:10.1016/j.socscimed.2018.03.010
 |
| © Adis |
Stevenson, M.,
Pandor, A., Hamilton, J., Stevens, J., Rowntree, C., Martyn-St James, M.,
Rawdin, A., Wong, R., 2018. Ponatinib for Treating Acute Lymphoblastic
Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology
Appraisal. Pharmacoeconomics. doi:10.1007/s40273-018-0624-7
Uttley, L.,
Bermejo, I., Ren, S., Martyn-St James, M., Wong, R., Scott, D.L., Young, A.,
Stevenson, M., 2018. Tofacitinib for Treating Rheumatoid Arthritis After the
Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group
Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 1–10.
doi:10.1007/s40273-018-0639-0